2 illness in COVID-19

- 3 Jesús F Bermejo-Martin^{1,2,3}*, Milagros González-Rivera^{4,5}*, Raquel Almansa^{1,2,3}*, Dariela
- 4 Micheloud⁶*, Marta Domínguez-Gil⁷*, Salvador Resino⁸*, Marta Martín-Fernández^{1,2},
- 5 Pablo Ryan Murua⁹, Felipe Pérez-García¹⁰, Luis Tamayo^{1,11}, Raúl Lopez-Izquierdo¹²,
- 6 Elena Bustamante¹³, César Aldecoa^{1,14,15}, José Manuel Gómez¹⁶, Jesús Rico-Feijoo^{1,15},
- 7 Antonio Orduña¹⁷, Raúl Méndez¹⁸, Isabel Fernández Natal¹⁹, Gregoria Megías²⁰,
- 8 Montserrat González-Estecha^{4,5}, Demetrio Carriedo²¹, Cristina Doncel ^{1,2,3}, Noelia Jorge
- 9 1,2,3, Félix del Campo²², José Antonio Fernández-Ratero²³, Wysali Trapiello ²⁴, Paula
- 10 González-Jiménez¹⁸, Guadalupe Ruiz²⁴, Alyson A. Kelvin^{25,26}, Ali Toloue
- 11 Ostadgavahi^{25,26}, Ruth Oneizat⁷, Luz María Ruiz⁷, Iria Miguéns⁶, Esther Gargallo⁶, Ioana
- 12 Muñoz⁶, Sara Pelegrin¹⁵, Silvia Martín^{1,15}, Pablo García Olivares¹⁶, Jamil Antonio
- 13 Cedeño¹⁶, Tomás Ruiz Albi²², Carolina Puertas⁴, Jose Ángel Berezo^{1,11}, Gloria Renedo¹³,
- 14 Rubén Herrán^{1,11}, Juan Bustamante-Munguira²⁷, Pedro Enríquez¹¹, Ramón Cicuendez¹³,
- 15 Jesús Blanco¹¹, Jesica Abadia²⁸, Julia Gómez Barquero²⁸, Nuria Mamolar¹³, Natalia
- 16 Blanca-López⁹, Luis Jorge Valdivia²¹, Belén Fernández Caso¹⁹, María Ángeles
- 17 Mantecón²⁰, Anna Motos^{3,29}, Laia Fernandez-Barat^{3,29}, Ricard Ferrer^{3,30}, Ferrán Barbé^{3,31},
- 18 Antoni Torres^{3,29 \(\Delta \)}, Rosario Menéndez^{3,18 \(\Delta \)}, José María Eiros^{7 \(\Delta \)}, David J Kelvin^{\(\Delta 25,26.)}
- 19 * These authors contributed equally
- 20 ^ΔThese authors contributed equally
- 22 1. Group for Biomedical Research in Sepsis (BioSepsis). Instituto de Investigación
- 23 Biomédica de Salamanca, (IBSAL), Paseo de San Vicente, 58-182, 37007 Salamanca,
- 24 Spain

- 25 2. Hospital Universitario Río Hortega, Calle Dulzaina, 2, 47012 Valladolid, Spain.
- 26 3. Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES),
- 27 Instituto de Salud Carlos III, Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain
- 28 4. Department of Laboratory Medicine, Hospital General Universitario Gregorio Marañón,
- 29 Calle del Dr. Esquerdo, 46, 28007 Madrid, Spain.
- 30 5. Department of Medicine, Faculty of Medicine, Universidad Complutense de Madrid,
- 31 Plaza de Ramón y Cajal, s/n, 28040 Madrid, Spain.
- 32 6. Emergency Department, Hospital General Universitario Gregorio Marañón, Calle del
- 33 Dr. Esquerdo, 46, 28007 Madrid, Spain.
- 34 7. Microbiology Service, Hospital Universitario Rio Hortega, Calle Dulzaina, 2, 47012
- 35 Valladolid, Spain
- 36 8. Viral Infection and Immunity Unit, Centro Nacional de Microbiología, Instituto de
- 37 Salud Carlos III, Ctra. de Pozuelo, 28, 28222 Majadahonda, Spain
- 38 9. Hospital Universitario Infanta Leonor, Av. Gran Vía del Este, 80, 28031 Madrid, Spain
- 39 10. Servicio de Microbiología Clínica, Hospital Universitario Príncipe de Asturias, Carr.
- 40 de Alcalá, s/n, 28805, Madrid, Spain
- 41 11. Intensive Care Unit, Hospital Universitario Rio Hortega, Calle Dulzaina, 2, 47012
- 42 Valladolid, Spain.
- 43 12. Emergency Department, Hospital Universitario Rio Hortega, Calle Dulzaina, 2, 47012
- 44 Valladolid, Spain.
- 45 13. Intensive Care Unit, Hospital Clínico Universitario de Valladolid. Av. Ramón y Cajal,
- 46 3, 47003 Valladolid, Spain

- 47 14. Department of Anesthesiology, Facultad de Medicina de Valladolid, Av. Ramón y48 Cajal, 7, 47005 Valladolid, Spain.
- 49 15. Anesthesiology and Reanimation Service, Hospital Universitario Rio Hortega, Calle50 Dulzaina, 2, 47012 Valladolid, Spain.
- 51 16. Intensive Care Unit. Hospital General Universitario Gregorio Marañón. Calle del Dr.
- 52 Esquerdo, 46, 28007 Madrid, Spain.
- 53 17. Microbiology Service, Hospital Clinico Universitario de Valladolid, Av. Ramón y 54 Cajal, 3, 47003 Valladolid, Spain.
- 55 18. Pulmonology Service, Hospital Universitario y Politécnico de La Fe, Avinguda de 56 Fernando Abril Martorell, 106, 46026, Valencia Spain
- 57 19. Clinical Microbiology Department. Complejo Asistencial Universitario de León. Calle 58 Altos de nava, s/n, 24001 León, Spain.
- 59 20. Microbiology Service, Hospital Universitario de Burgos, Av. Islas Baleares, 3, 0900660 Burgos, Spain
- 61 21. Intensive Care Unit. Complejo Asistencial Universitario de León. Calle Altos de nava,62 s/n, 24001 León, Spain.
- 63 22. Pneumology Service, Hospital Universitario Río Hortega / Biomedical Engineering 64 Group, Universidad de Valladolid, Calle Dulzaina, 2, 47012 Valladolid, Spain.
- 65 23. Intensive Care Unit. Hospital Universitario de Burgos, Av. Islas Baleares, 3, 0900666 Burgos, Spain.
- 67 24. Clinical Analysis Service. Hospital Clínico Universitario de Valladolid, Av. Ramón y68 Cajal, 3, 47003 Valladolid, Spain

70 University, Halifax, Nova Scotia, B3H 4R2, Canada

- 71 26. International Institute of Infection and Immunity, Shantou University Medical College,
- 72 22 Xinling Rd, Jinping, Shantou, Guangdong, China.
- 73 27. Department of Cardiovascular Surgery, Hospital Clínico Universitario de Valladolid.
- 74 Av. Ramón y Cajal, 3, 47003 Valladolid, Spain
- 75 28. Infectious diseases clinic, Internal Medicine Department, Hospital Universitario Río
- 76 Hortega, Valladolid, Calle Dulzaina, 2, 47012 Valladolid, Spain
- 77 29. Department of Pulmonology, Hospital Clinic de Barcelona, Universidad de Barcelona,
- 78 Institut D investigacions August Pi I Sunyer (IDIBAPS), Carrer del Rosselló, 149, 08036
- 79 Barcelona, Spain.
- 80 30. Intensive Care Department, Vall d'Hebron Hospital Universitari. SODIR Research
- 81 Group, Vall d'Hebron Institut de Recerca, Passeig de la Vall d'Hebron, 119, 08035
- 82 Barcelona, Spain.
- 83 31. Respiratory Department, Institut Ricerca Biomedica de Lleida, Av. Alcalde Rovira
- 84 Roure, 80, 25198 Lleida, Spain.
- 85 Corresponding author: David J Kelvin Department of Microbiology and Immunology,
- 86 Dalhousie University, Halifax, Nova Scotia, B3H 4R2, Canada. E-mail address:
- 87 dkelvin@jidc.org.

88

89

91 Abstract

92 **Background:** Severe COVID-19 is characterized by clinical and biological manifestations 93 typically observed in sepsis. SARS-CoV-2 RNA is commonly detected in nasopharyngeal 94 swabs, however viral RNA can be found also in peripheral blood and other tissues. 95 Whether systemic spreading of the virus or viral components plays a role in the 96 pathogenesis of the sepsis-like disease observed in severe COVID-19 is currently 97 unknown. 98 Methods: We determined the association of plasma SARS-CoV-2 RNA with the 99 biological responses and the clinical severity of patients with COVID-19. 250 patients with 100 confirmed COVID-19 infection were recruited (50 outpatients, 100 hospitalised ward 101 patients, and 100 critically ill). The association between plasma SARS-CoV-2 RNA and 102 laboratory parameters was evaluated using multivariate GLM with a gamma distribution. 103 The association between plasma SARS-CoV-2 RNA and severity was evaluated using 104 multivariate ordinal logistic regression analysis and Generalized Linear Model (GLM) 105 analysis with a binomial distribution. 106 **Results:** The presence of SARS-CoV-2-RNA viremia was independently associated with a 107 number of features consistently identified in sepsis: 1) high levels of cytokines (including 108 CXCL10, CCL-2, IL-10, IL-1ra, IL-15, and G-CSF); 2) higher levels of ferritin and LDH; 109 3) low lymphocyte and monocyte counts 4) and low platelet counts. In hospitalised 110 patients, the presence of SARS-CoV-2-RNA viremia was independently associated with 111 critical illness: (adjusted OR= 8.30 [CI95%=4.21 - 16.34], p < 0.001). CXCL10 was the 112 most accurate identifier of SARS-CoV-2-RNA viremia in plasma (area under the curve 113 (AUC), [CI95%], p) = 0.85 [0.80 – 0.89), <0.001]), suggesting its potential role as a 114 surrogate biomarker of viremia. The cytokine IL-15 most accurately differentiated clinical

115 ward patients from ICU patients (AUC: 0.82 [0.76 – 0.88], <0.001).

116 Conclusions: systemic dissemination of genomic material of SARS-CoV-2 is associated 117 with a sepsis-like biological response and critical illness in patients with COVID-19. RNA 118 viremia could represent an important link between SARS-CoV-2 infection, host response 119 dysfunction and the transition from moderate illness to severe, sepsis-like COVID-19 120 disease. **Key words:** SARS-CoV-2, cytokine, sepsis, COVID-19, plasma, viremia, ICU

142 With well over 26 million cases and 863,516 deaths globally, Coronavirus disease 2019
143 (COVID-19) has become the top economic and health priority worldwide [1]. Among
144 hospitalized patients, around 10–20% are admitted to the intensive care unit (ICU), 3–10%
145 require intubation and 2–5% die [2]. Severe COVID-19 is characterized by clinical and
146 biological manifestations typically observed in sepsis or septic shock, including cold
147 extremities and weak peripheral pulse, even in the absence of overt hypotension [3].
148 Patients with severe COVID-19 show marked signs of dysregulated host response(s) to
149 infection, which are also observed in sepsis: this includes elevation of acute phase reactants
150 and cytokines, transaminases, and ferritin, the activation of the coagulation pathways, the
151 presence of lymphopenia and low platelet counts, the elevation of biomarkers of
152 endothelial dysfunction, and the emergence of signs of profound immunological alteration
153 [4] [5] [6]. It is not surprising that severe COVID-19 has been proposed as a "viral
154 sepsis" [3] [7].

155 SARS-CoV-2 RNA is commonly detected in nasopharyngeal swabs; however viral RNA
156 can be found in sputum, lung samples, peripheral blood, serum, stool samples, and to a
157 limited extent urine [8] [9] [10] [11]. While the lungs are most often affected, severe
158 COVID-19 can also induce inflammatory cell infiltration, haemorrhage, and degeneration
159 or necrosis in extra-pulmonary organs (spleen, lymph nodes, kidney, liver, central nervous
160 system) [3]. Whether systemic distribution of the virus or viral components plays a role in
161 the pathogenesis of the "sepsis-like" clinical presentation [3] or in the dysregulated
162 response to the infection observed in severe COVID-19 is currently unknown.

163 In this study, by using a integrative approach, we evaluated the impact of SARS-CoV-2
164 RNA viremia on a number of biological parameters altered both in COVID-19 and sepsis.

165 We also studied the association between the presence of SARS-CoV-2 RNA in peripheral 166 blood plasma and disease severity.

184 **Study design**: 250 adult patients with a positive nasopharyngeal swab polymerase chain 185 reaction (PCR) test for SARS-CoV-2 administered at participating hospitals were recruited 186 during the first pandemic wave in Spain from March 16th to the 15th of April 2020. The 187 patients recruited were of three different categories. The first corresponded to patients 188 examined at an emergency room and discharged within the first 24 hours (outpatients 189 group, n=50). The second group were patients hospitalized to pneumology, infectious 190 diseases or internal medicine wards (wards group, n=100). Patients who required critical 191 care or died during hospitalization were excluded from this group, in order to have a group 192 of clear moderate severity. The third group corresponded to patients admitted to the ICU 193 (n=100). Patient's recruited by participating hospital are detailed in the additional file 1. 194 This is a preliminary report on the biomarkers' sub-study of the CIBERES-UCI-COVID 195 study registered at Clinicaltrials.gov with the identification NCT04457505.

196 **Blood samples:** Plasma from blood collected in EDTA tubes samples was obtained from 197 the three groups of patients in the first 24 hours following admission to the emergency 198 room, to the ward, or to the ICU, at a median collection day since disease onset of 7, 8 and 199 10 respectively, and also. from 20 blood donors (10 men and 10 women).

200 **Laboratory works:** immunological mediators were profiled in plasma using the Ella201 SimplePlexTM (San Jose, California, U.S.A) immunoassay. RNA was extracted from 150
202 μl of plasma using an automated system, eMAG® from bioMérieux® (Marcy l'Etoile,
203 France). Detection of SARS-CoV-2 RNA was performed in five μl of the eluted solution
204 using the CLART® COVID-19 platform from Genomica® (Madrid, Spain). IgG specific
205 for the Nucleocapsid Protein of SARS-CoV-2 was detected in 150 μl of plasma using the
206 Abbott Architect SARS-CoV-2 IgG Assay (Illinois, U.S.A).

207 **Statistical analysis:** Statistical analysis was performed by using Statistical Package for the 208 Social Science (SPSS) 20.0 (SPSS INC, Chicago, IL, U.S.A), Stata 15.0 (StataCorp, Texas, 209 U.S.A) and Minitab 19.2 software. For the demographic and clinical characteristics of the 210 patients, the differences between groups were assessed using the Chi-square test for 211 categorical variables. Differences for continuous variables were assessed by using the 212 Kruskal-Wallis test with post hoc tests adjusting for multiple comparisons. Statistical 213 association analysis was performed using different regression models to assess the 214 relationship between viremia and outcome variables. An ordinal logistic regression (OLR) 215 model was used considering the outcome variable as ordinal (outpatients, wards, and ICU), 216 providing an odds ratio (OR). Generalized Linear Models (GLM) with binomial 217 distribution were used when the outcome variable was dichotomous (outpatients vs. wards, 218 and wards vs. ICU), also providing an odds ratio (OR). GLM with a gamma distribution 219 (log-link) was used when the outcome variable was continuous, providing arithmetic mean 220 ratios (AMR). In all cases, the analysis was performed first without adjustment and was 221 later adjusted for the most relevant covariates in our study. P-values were corrected using 222 the false discovery rate (FDR) with the Benjamini and Hochberg (q-values) procedure. 223 224 225 226 227 228

230 Results

231 Clinical characteristics of the patients (Table 1): Patients diagnosed with SARS-CoV-2 232 infection based on a positive nasopharyngeal test and requiring hospitalization (either 233 general ward or ICU) were older (median 64 years of age for ward and 66 years for ICU) 234 than those patients discharged to their home from the ER (median age 48 years of age). 235 There were no significant differences regarding age between ward and ICU hospitalised 236 patients. Critically ill patients (ICU admitted) were more frequently male than those in the 237 other groups. Comorbidities of obesity, hypertension, dyslipidemia and type II diabetes 238 were more commonly found in patients requiring hospitalization, with no significant 239 differences found in the comorbidities profile between critically ill and non-critically ill 240 hospitalized patients. ICU patients showed significantly lower levels of O₂ saturation at the 241 time of admission to the ICU compared to other patients admitted to the ER or the ward. 242 100% of ICU patients presented with pulmonary infiltrates of whom 93 % also had 243 bilateral pneumonia, these findings were significantly higher than the incidence of 244 pulmonary infiltrates and bilateral pneumonia found in the other two groups. Glucose 245 levels were higher in the group of critically ill patients, who also showed higher values of 246 INR, D-dimers, LDH, GPT, ferritin, C-reactive protein and lower haematocrit. ICU 247 patients showed pronounced lymphopenia and lower monocyte counts; however, 248 neutrophil counts were increased. ICU patients more frequently received experimental 249 treatments during their hospitalization period, including hydroxicloroquine, corticoids, 250 remdesivir, tocilizumab, lopinavir/ritonavir or beta-interferon. ICU patients stayed longer 251 in the hospital, with 48 % fatalities reported in this group. The number of missing values 252 for the variables registered in this study are reported in the additional file 2.

255 Impact of SARS-CoV-2-RNA viremia on laboratory parameters:

256 Multivariate GLM analysis showed that SARS-CoV-2-RNA viremia was an independent 257 marker of high levels of ferritin, LDH and high levels of chemokines (CXCL10, CCL-2), 258 cytokines (IL-15, IL-10, IL-1ra) and GCS-F (Figure 1 and additional file 3). In contrast, 259 viremia was independently associated to low lymphocyte, monocyte and platelet counts 260 and low levels of IL-4 in plasma (Figure 1 and additional file 3). Patients requiring 261 hospitalization in the ward showed significantly increased levels of IL-10, CXCL0, IL-1ra, 262 IL-6 and TNF-α compared to outpatients. Critically ill patients showed significantly higher 263 levels of GM-CSF, CXCL10, CCL2, IL-10, IL-6 and IL-15 compared to ward patients and 264 outpatients (figure 2 and additional file 4).

265 **Prevalence of SARS-CoV-2-RNA viremia and specific SARS-Cov-2 IgG.** To assess the 266 possible systemic nature of SAS-CoV-2 infections in hospitalized patients we determined 267 the presence of SARS-CoV-2 RNA in plasma. As depicted in table 1 and figure 3, the 268 frequency of SARS-CoV-2-RNA viremia was higher the critically ill patients (82%) 269 compared to ward patients (36%) and outpatients (22%) (p<0.001). No statistical 270 differences were found in plasma viral RNA between the outpatients and the patients in the 271 ward (p = 0.081). Critically ill patients also had a higher frequency of specific SARS-CoV-272 2 IgG responses than the other groups (70% in ICU compared to 52% and 49% in the 273 outpatients and ward groups, p < 0.05, table 1 and figure 3). No significant differences 274 were found between the group of outpatients and those admitted to the ward.

275 **SARS-CoV-2-RNA viremia and disease severity.** When the association between viremia 276 and clinical status was evaluated, multivariate ordinal logistic regression analysis revealed 277 that SARS-CoV-2-RNA viremia was a predictor of severity across the three categories 278 considered in our study [OR= 8.24, p < 0.001, (CI 95%= 4.71; 14.41)] (see additional file 279 5). When we compared outpatients with admitted ward patients, multivariate GLM

280 analysis showed that viremia was not significantly associated with either group (Table 2). 281 In contrast, when the group of ward patients was compared to ICU patients, multivariate 282 GLM analysis showed that viremia was strongly associated with patient severity requiring 283 critical care [OR = 8.3, p < 0.001, (CI 95% = 4.21-16.34)] (Table 2). In the patients 284 admitted to the ICU, no significant difference in the prevalence of SARS-CoV-2-RNA was 285 found between survivors and non survivors: 42 out of 48 of non survivors had viremia 286 (87.5%), while 40 out of 52 survivors (76.9%) had viremia, p = 0.169.

301 Discussion

302 Our study demonstrates that the presence of SARS-CoV-2 RNA in the plasma of patients 303 with COVID-19 is associated to a number of biological alterations typically found in 304 sepsis. Viremia was an independent predictor of high levels of chemokines (CXCL10, 305 CCL2) and cytokines (IL-10, IL-1ra, IL-15, G-CSF). These chemokines and cytokines 306 have also been reported to be elevated in sepsis [12] [13] [14] [15]. Recognition of viral 307 RNA by endosomal receptors such as toll like receptor 7 (TLR7) in human plasmacytoid 308 dendritic cells and B cells, or TLR8 in myeloid cells, activate intracellular signalling 309 pathways enhancing cytokine production [16]. In fact, it has recently been demonstrated 310 that SARS-CoV-2 genome has more single-stranded RNA fragments that could be 311 recognized by TLR7/8 than the SARS-CoV-1 genome, which suggests the potential of 312 SARS-CoV-2 to induce hyperactivation of innate immunity [17]. In our study, CXCL10 313 was the most accurate identifier of viremia in plasma (area under the curve (AUC), 314 [CI95%], p) = 0.85 [0.80 – 0.89), <0.001), supporting its potential role as a surrogate 315 biomarker of SARS-CoV RNA viremia. Signalling via the CXCL10 cognate receptor, 316 CXCR3, mediates immunopathology during other highly pathogenic respiratory virus 317 infections such as H5N1 influenza virus [18]. CCL2 is one of the key chemokines that 318 regulate migration and infiltration of monocytes/macrophages [19]. We had already 319 demonstrated that SARS patients had increased levels of CXCL10 and CCL2 in serum 320 during the early onset of symptoms [20]. IL-10 and IL-1ra are major immunomodulatory 321 cytokines inducing immunosuppression. Zhao Y et al reported IL-10 and IL-1ra to be 322 associated with the severity of COVID-19 [21]. Whether elevation of IL-10 and IL-1RA 323 represents a mechanism of viral evasion or an attempt of the immune system to control an 324 exuberant inflammatory response remains to be elucidated [22] [23]. The association 325 between SARS-CoV-2-RNA viremia and IL-15 is also especially intriguing, since IL-15

326 was the cytokine which most accurately differentiated clinical ward patients from ICU 327 patients (AUC: 0.82 [0.76 – 0.88], <0.001). Previously, we identified IL-15 as a signature 328 of critical illness in the H1N1 2009 influenza pandemics [24]. IL-15 is a pleiotropic 329 cytokine that induces T-cell proliferation and enhances natural killer (NK) cell cytotoxicity 330 [25]. It may also play an essential role in T cell or NK cell mediated tissue destruction 331 [26]. During Hantavirus infection, IL-15 drives a massive NK cell response with high 332 levels of IL-15 associated with severe disease and fatal outcome [27]. Recently, it was 333 reported that circulating NK cells were elevated in COVID-19 severe patients [28] 334 illustrating the potentially important role of IL-15 in regulating NK function during 335 COVID-19 pathogenesis. The role of G-CSF in COVID-19 is currently under discussion. 336 In patients with cancer and COVID-19, administration of G-CSF was associated with an 337 increased need for high oxygen supplementation and death [29]. It has been proposed that 338 G-CSF could worsen lung function by causing neutrophil infiltration [30]. During the 2009 339 influenza pandemics, we demonstrated that, in critically patients, high levels of G-CSF in 340 plasma translated into diminished survival [31]. 341 Viremia was also associated with higher levels of ferritin in COVID-19 patients in our 342 study. Ferritin is an acute-phase reactant, commonly triggered by inflammation and 343 infection. Sepsis patients frequently present with elevated serum ferritin, where it is related 344 to poor clinical outcome [32]. In a recent metanalysis, Khinda et al evidenced also the 345 association between ferritin and mortality in COVID-19 [33]. Viremia also correlated with 346 higher levels of LDH, a marker of necrosis and cellular injury. High levels of LDH are 347 increased in non survivors in sepsis [34] and also in COVID-19 [33]. The association of 348 viremia with high LDH levels and lower O2 saturation supports viral involvement in the 349 genesis of tissue damage and respiratory failure in patients with severe COVID-19.

350 Another shared hallmark of sepsis and COVID-19 is the presence of lymphopenia and 351 monocytopenia [35] [36] [37] [4]. In COVID-19 patients, our study demonstrates that the 352 presence of viremia was associated with lower lymphocyte and monocyte counts in 353 peripheral blood. In sepsis, the presence of low platelet counts is assessed in the Sequential 354 Organ failure score (SOFA) as a parameter indicating coagulation failure [38]. In our 355 study, the presence of viremia in COVID-19 patients was associated to lower platelet 356 counts. Even though platelet counts did not show significant variation across the three 357 severity groups (Table 1), those patients with SARS-CoV-2-RNA viremia showed 358 significantly lower platelet counts than the other patients (198,000 vs 230,000 cells/mm3, p 359 = 0.003). In turn, critically ill non survivors showed lower platelet counts than survivors 360 (179,000 vs 221,000 cells/mm3, p = 0.001). 361 Our work identifies a connection between viremia and severe clinical presentation of 362 COVID-19. SARS-CoV-2 viral RNA is detected in the plasma of the vast majority of those 363 COVID-19 patients admitted to the ICU (82%). In hospitalized COVID-19 patients, the

362 COVID-19. SARS-CoV-2 viral RNA is detected in the plasma of the vast majority of those 363 COVID-19 patients admitted to the ICU (82%). In hospitalized COVID-19 patients, the 364 presence of SARS-CoV-2-RNA viremia translates into an 8-fold increase in the risk of 365 presenting critical illness, independently of age, sex and major comorbidities. In turn, 366 critically ill COVID-19 patients were those showing the greatest alterations in cytokine, 367 ferritin, LDH, lymphocyte and monocyte levels. These findings identify viremia as an 368 important link between SARS-CoV-2 infection and the development of sepsis-like disease 369 in COVID-19 patients, suggesting that the presence of viraemic SARS-CoV-2 RNA in the 370 plasma could be playing a major role in the transition of moderate illness to severe 371 COVID-19. The underlying mechanisms or processes leading to the viraemic state are not 372 understood at this time, however, lymphopenia, hypercytokinemia, and increased 373 expression of IL-10 and IL-1RA may represent dysfunctional host responses to the virus 374 allowing for dissemination of viral components and perhaps the virus itself. The possibility

376 management point of view recognizing severe COVID-19 as a sepsis-like disease suggests

377 that targeting the virus as an infectious agent causing sepsis would require early

378 intervention with antiviral strategies (drugs or convalescent / hyperimmune sera,

379 monoclonal antibodies), similar to treatment of bacterial sepsis with antibiotics.

380 Furthermore, using CXCL-10 and IL-15 as surrogate markers for viremia and critical

381 illness could facilitate indirect identification of the "septic-like" state, as proteins are easier

382 to profile than viremic RNA.

383 Finally, most ICU patients with SARS-CoV-2-RNA viremia had already developed a

384 specific IgG response against the virus (70.7 %), which would support the notion that

385 continued viral replication is a persistent event during antibody responses.

386 As a limitation of our study is we did not determine if the findings of viral RNA in plasma

387 reflects the presence of live virus in peripheral blood. However, the SARS-CoV-2 virus

388 has been reported to be difficult to culture from blood. [9] Another limitation of our study

389 is that we did not evaluate viral load. Our group is currently working in determining viral

390 load quantification and viral growth from plasma.

391 Conclusions

392 Systemic dissemination of SARS-CoV-2 genomic material in patients with COVID-19 is

393 strongly associated with biological responses typically observed in sepsis. RNA-viremia is

394 a marker of critical illness in COVID-19 patients. Prompt identification of viremia could

395 help to early detect those patients at risk of clinical deterioration. Early control of viremia

396 could contribute to improve survival.

399 List of abbreviations

400 SARS-CoV-2: Severe acute Respiratory Syndrom-Coronavirus-2

401 LDH: Lactate dehydrogenase

402 G-CSF: Granulocyte colony-stimulating factor

403 TLR: toll like receptor

405 **Declarations**

404

406 Ethics approval and consent to participate: The study was approved by the Committee

407 for Ethical Research of the coordinating institution, "Comite de Etica de la Investigacion

408 con Medicamentos del Area de Salud de Salamanca", code PI 2020 03 452. Informed

409 consent was obtained orally when clinically possible. In the remaining cases, the informed

410 consent waiver was authorized by the Ethics committee.

411 Consent for publication: not applicable

412 Availability of data and materials: the datasets generated and/or analysed during the

413 current study are not publicly available since they are still under elaboration for publication

414 by the authors but are available from the corresponding author on reasonable request.

415 Competing interests

416 The authors declare that they have no competing interests

417 Funding

418 This work was supported by awards from the Canadian Institutes of Health Research, the

419 Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding initiative (CIHR

420 OV2 – 170357), Research Nova Scotia (DJK), Atlantic Genome/Genome Canada (DJK),

421 Li-Ka Shing Foundation (DJK), Dalhousie Medical Research Foundation (DJK), the
422 "Subvenciones de concesión directa para proyectos y programas de investigación del virus
423 SARS□CoV2, causante del COVID□19", FONDO - COVID19, Instituto de Salud Carlos
424 III (COV20/00110, CIBERES, 06/06/0028), (AT) and finally by the "Convocatoria
425 extraordinaria y urgente de la Gerencia Regional de Salud de Castilla y León, para la
426 financiación de proyectos de investigación en enfermedad COVID-19" (GRS COVID
427 53/A/20) (CA). DJK is a recipient of the Canada Research Chair in Translational
428 Vaccinology and Inflammation. The funding sources did not play any role neither in the
429 design of the study and collection, not in the analysis, in the interpretation of data or in
430 writing the manuscript.

431 **Authors 'contribution:** JFBM, DJK, JB, RF, FB, AT and RM designed the study. JFBM 432 and DJK wrote the manuscript and interpreted the data. RA coordinated the clinical study 433 and drafted the figures. MGR, DM, PR, FPG, LT, RLI, EB, CA, JMG, JR, RM, MIF, GM, 434 MGE, DC, FDC, JFR, WT, PGJ, GR, IM, EG,IM, SP, SM, PGO, JAC, TRA, CP, JAB, 435 GR, RH, JB, PE, RC, JA, JGB, NM, NBL, LJV, BFC, MAM recruited the patients and /or 436 collected the clinical data. MDG, AO, RO, LMR and JME performed the assays for the 437 detection of SARS-CoV-2 IgG and viremia. CD and NJ profiled the immunological 438 mediators. SR and MMF developed the statistical analysis and drafted the figures. AAK, 439 ATO, AM and LF performed the literature search. All authors read and approved the final 440 manuscript.

442 **Ackowledgements:** we thank SEIMC-GESIDA Foundation for the scientific sponsoring of 443 this project. We thank also the "Centro de Hemoterapia y Hemodonación de Castilla y 444 León, CHEMCYL", which provided the plasma simples used in the healthy control group.

References:

- 1. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at
- Johns Hopkins University (JHU) [Internet]. Available from:
- 448 https://coronavirus.jhu.edu/map.html
- 2. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics
- of Coronavirus Disease 2019 in China. N Engl J Med. 2020;
- 451 3. Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and viral sepsis:
- observations and hypotheses. Lancet. 2020;395:1517–20.
- 4. Bao J, Li C, Zhang K, Kang H, Chen W, Gu B. Comparative analysis of laboratory
- indexes of severe and non-severe patients infected with COVID-19. Clin Chim Acta.
- 455 2020;509:180–94.
- 5. Hupf J, Mustroph J, Hanses F, Evert K, Maier LS, Jungbauer CG. RNA-expression of
- 457 adrenomedullin is increased in patients with severe COVID-19. Crit Care. 2020;24:527.
- 458 6. Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, et al. COVID-19:
- immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther.
- 460 2020;5:128.
- 7. López-Collazo E, Avendaño-Ortiz J, Martín-Quirós A, Aguirre LA. Immune
- Response and COVID-19: A mirror image of Sepsis. Int J Biol Sci. 2020;16:2479–89.
- 8. Cevik M, Bamford CGG, Ho A. COVID-19 pandemic—a focused review for
- clinicians. Clinical Microbiology and Infection. Elsevier; 2020;26:842–7.
- 9. Zhang W, Du R-H, Li B, Zheng X-S, Yang X-L, Hu B, et al. Molecular and
- 466 serological investigation of 2019-nCoV infected patients: implication of multiple
- shedding routes. Emerging Microbes & Infections. Taylor & Francis; 2020;9:386–9.
- 10. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable Serum Severe
- 469 Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely
- 470 Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With
- 471 Coronavirus Disease 2019. Clin Infect Dis [Internet]. [cited 2020 Jul 6]; Available
- 472 from: https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa449/5821311
- 473 11. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease
- severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-
- March 2020: retrospective cohort study. BMJ. 2020;369:m1443.
- 12. Jekarl DW, Kim JY, Ha JH, Lee S, Yoo J, Kim M, et al. Diagnosis and Prognosis of
- 477 Sepsis Based on Use of Cytokines, Chemokines, and Growth Factors. Dis Markers.
- 478 2019;2019:1089107.
- 479 13. Pierrakos C, Vincent J-L. Sepsis biomarkers: a review. Crit Care. 2010;14:R15.
- 480 14. Pierrakos C, Velissaris D, Bisdorff M, Marshall JC, Vincent J-L. Biomarkers of
- sepsis: time for a reappraisal. Crit Care. 2020;24:287.

- 482 15. Chung K-P, Chang H-T, Lo S-C, Chang L-Y, Lin S-Y, Cheng A, et al. Severe
- 483 lymphopenia is associated with elevated plasma interleukin-15 levels and increased
- 484 mortality during severe sepsis. Shock. 2015;43:569–75.
- 485 16. Birra D, Benucci M, Landolfi L, Merchionda A, Loi G, Amato P, et al. COVID 19:
- a clue from innate immunity. Immunol Res. 2020;68:161–8.
- 487 17. Moreno-Eutimio MA, López-Macías C, Pastelin-Palacios R. Bioinformatic analysis
- 488 and identification of single-stranded RNA sequences recognized by TLR7/8 in the
- SARS-CoV-2, SARS-CoV, and MERS-CoV genomes. Microbes Infect. 2020;22:226–9.
- 490 18. Cameron CM, Cameron MJ, Bermejo-Martin JF, Ran L, Xu L, Turner PV, et al.
- 491 Gene expression analysis of host innate immune responses during Lethal H5N1
- 492 infection in ferrets. J Virol. 2008;82:11308–17.
- 493 19. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte Chemoattractant
- 494 Protein-1 (MCP-1): An Overview. J Interferon Cytokine Res. 2009;29:313–26.
- 495 20. Cameron MJ, Bermejo-Martin JF, Danesh A, Muller MP, Kelvin DJ. Human
- 496 immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res.
- 497 2008;133:13–9.
- 498 21. Zhao Y, Qin L, Zhang P, Li K, Liang L, Sun J, et al. Longitudinal COVID-19
- 499 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild
- 500 disease. JCI Insight. 2020;5.
- 501 22. Rojas JM, Avia M, Martín V, Sevilla N. IL-10: A Multifunctional Cytokine in Viral
- 502 Infections. J Immunol Res [Internet]. 2017 [cited 2020 Jul 16];2017. Available from:
- 503 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337865/
- 504 23. Couper KN, Blount DG, Riley EM. IL-10: The Master Regulator of Immunity to
- Infection. The Journal of Immunology. American Association of Immunologists;
- 506 2008;180:5771–7.
- 507 24. Bermejo-Martin JF, Ortiz de Lejarazu R, Pumarola T, Rello J, Almansa R, Ramírez
- 508 P, et al. Th1 and Th17 hypercytokinemia as early host response signature in severe
- pandemic influenza. Crit Care. 2009;13:R201.
- 25. Perera P-Y, Lichy JH, Waldmann TA, Perera LP. The role of interleukin-15 in
- 511 inflammation and immune responses to infection: implications for its therapeutic use.
- 512 Microbes Infect. 2012;14:247–61.
- 513 26. Jabri B, Abadie V. IL-15 functions as a danger signal to regulate tissue-resident T
- cells and tissue destruction. Nat Rev Immunol. 2015;15:771–83.
- 515 27. Klingström J, Smed-Sörensen A, Maleki KT, Solà-Riera C, Ahlm C, Björkström
- 516 NK, et al. Innate and adaptive immune responses against human Puumala virus
- 517 infection: immunopathogenesis and suggestions for novel treatment strategies for severe
- 518 hantavirus-associated syndromes. J Intern Med. 2019;285:510–23.

- 1520 lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2
- infected patients. EBioMedicine. 2020;55:102763.
- 522 29. Morjaria S, Zhang A, Kaltsas Md A, Parameswaran R, Patel D, Zhou W, et al. The
- 523 Effect of Neutropenia and Filgrastim (G-CSF) in Cancer Patients With COVID-19
- 524 Infection. medRxiv. 2020;
- 525 30. Lazarus HM, Gale RP. G-CSF and GM-CSF Are Different. Which One Is Better for
- 526 COVID-19? AHA. Karger Publishers; 2020;1–4.
- 31. Almansa R, Socias L, Ramirez P, Martin-Loeches I, Vallés J, Loza A, et al.
- 528 Imbalanced pro- and anti-Th17 responses (IL-17/granulocyte colony-stimulating factor)
- predict fatal outcome in 2009 pandemic influenza. Crit Care. 2011;15:448.
- 32. Lachmann G, Knaak C, Vorderwülbecke G, La Rosée P, Balzer F, Schenk T, et al.
- Hyperferritinemia in Critically III Patients. Crit Care Med. 2020;48:459–65.
- 532 33. Khinda J, Janjua NZ, Cheng S, van den Heuvel ER, Bhatti P, Darvishian M.
- Association between markers of immune response at hospital admission and COVID-19
- disease severity and mortality: A meta-analysis and meta-regression. J Med Virol. 2020;
- 535 34. Lu J, Wei Z, Jiang H, Cheng L, Chen Q, Chen M, et al. Lactate dehydrogenase is
- associated with 28-day mortality in patients with sepsis: a retrospective observational
- 537 study. J Surg Res. 2018;228:314–21.
- 538 35. Rubio I, Osuchowski MF, Shankar-Hari M, Skirecki T, Winkler MS, Lachmann G,
- et al. Current gaps in sepsis immunology: new opportunities for translational research.
- 540 Lancet Infect Dis. 2019;19:e422–36.
- 36. Chung H, Lee JH, Jo YH, Hwang JE, Kim J. Circulating Monocyte Counts and its
- Impact on Outcomes in Patients With Severe Sepsis Including Septic Shock. Shock.
- 543 2019;51:423–9.
- 37. Bermejo-Martin JF, Almansa R, Menendez R, Mendez R, Kelvin DJ, Torres A.
- Lymphopenic community acquired pneumonia as signature of severe COVID-19.
- Journal of Infection. 2020;
- 38. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The
- 548 SOFA (Sepsis-related Organ Failure Assessment) score to describe organ
- 549 dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the
- European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707–10.

551

| Outpatients (1) | Ward (2) | ICU (3) | p value | p value | p value | |
|-----------------|----------|---------|----------|----------|------------|--|
| | | | (1 vs 2) | (1 vs 3) | (2 vs 3) | |

Conflicts of interests: the authors declare no conflicts of interests regarding this submission

| ı |
|---|

| | K (mEq/L) [median (IQR)] | 3.90 (0.50) | 4.10 (0.68) | 3.95 (0.90) | - | - | - |
|-----------------|---|--------------|---------------|--------------|---------|---------|---------|
| Measurements at | Platelets (cell x 10 ³ /µl) [median (IQR)] | 223 [97] | 207 [113] | 204 [126] | - | - | - |
| diagnosis | INR [median (IQR)] | 1.04 (0.10) | 1.11 (0.13) | 1.22 (0.22) | 0.001 | < 0.001 | < 0.001 |
| | D Dimer (pg/ml) [median (IQR)] | 795278 | 1597362.50 | 6182104.50 | < 0.001 | < 0.001 | < 0.001 |
| | | [828234] | [2024704] | [52690922] | | | |
| | LDH (UI/L) [median (IQR)] | 214 (73) | 278 (138) | 496 (285) | 0.002 | < 0.001 | < 0.001 |
| | GPT (UI/L) [median (IQR)] | 27 (43) | 29 (29) | 44 (44.50) | n.s. | n.s. | 0.016 |
| | | 359507 | 523805 | 923687 | | < 0.001 | 0.002 |
| | Ferritin (pg/ml) [median (IQR)] | [458748] | [534757] | [1526492] | n.s. | | |
| | CRP (mg/dl) [median (IQR)] | 1.40 (3.50) | 40.90 (89.18) | 91 (182.10) | < 0.001 | < 0.001 | 0.031 |
| | Haematocrit (%) [median (IQR)] | 43.15 (4.72) | 42.50 (6.50) | 38.15 (6.48) | n.s. | < 0.001 | < 0.001 |
| | WBC (cells/mm3) [median (IQR)] | 6450 (2815) | 7005 (4115) | 9145 (6613) | n.s. | < 0.001 | 0.006 |
| | Lymphocytes (cells/mm3) [median | 1400 (805) | 1000 (433) | 540 (445) | < 0.001 | < 0.001 | < 0.001 |
| | Neutrophils (cells/mm3) [median | 4260 (2625) | 5250 (3918) | 8300 (5880) | 0.046 | < 0.001 | < 0.001 |
| | Monocytes (cells/mm3) [median (IQR)] | 500 (300) | 400 (300) | 300 (280) | n.s. | < 0.001 | 0.019 |
| | Eosinophils (cells/mm3) [median (IQR)] | 0 (100) | 0 (40) | 0 (6) | n.s. | n.s. | n.s. |
| | Basophils (cells/mm3) [median (IQR)] | 0 (0) | 0 (20) | 5.25 (17) | 0.001 | < 0.001 | n.s. |

Table 1: Clinical characteristics of the patients: continuous variables are represented as [median, (interquartile range, IQR)]; categorical variables are represented as [%, (n)].; INR, International Normalized Ratio; n.s., not significant; n.a., not applicable.

COPD (Chronic obstructive pulmonary disease), HIV (Human Immunodeficiency

Virus), INR (International Normalized Ratio), LDH (Lactic Acid Dehydrogenase), GPT (glutamic-pyruvate transaminase); CRP (C-reactive protein), WBC (white blood cell).


GLM (outpatients vs wards) GLM (wards vs ICU)


| | | | CI 95% | | | | CI 95% | |
|-----------------|------|---------|--------|-------|------|---------|--------|-------|
| | OR | p | lower | upper | OR | p | lower | upper |
| Viremia | 2.12 | 0.10 | 0.86 | 5.20 | 8.30 | < 0.001 | 4.21 | 16.34 |
| Age | 1.06 | < 0.001 | 1.03 | 1.09 | 1.00 | 0.97 | 0.98 | 1.02 |
| Sex | 1.06 | 0.88 | 0.48 | 2.32 | 1.86 | 0.06 | 0.97 | 3.56 |
| Obesity | 4.89 | 0.05 | 1.02 | 23.53 | 1.11 | 0.78 | 0.52 | 2.36 |
| Hypertension | 1.19 | 0.71 | 0.48 | 2.95 | 0.90 | 0.77 | 0.44 | 1.83 |
| Cardiac disease | 1.69 | 0.55 | 0.29 | 9.83 | 0.69 | 0.51 | 0.23 | 2.07 |
| Asthma | 1.02 | 0.98 | 0.23 | 4.43 | 0.26 | 0.15 | 0.04 | 1.62 |
| Dyslipidemia | 1.63 | 0.33 | 0.60 | 4.40 | 0.84 | 0.66 | 0.40 | 1.79 |


Table 2: Multivariate generalized linear model with binomial distribution to assess the association between viremia and hospitalization at the wards in the comparison (outpatients vs wards) (left) and the association between viremia and hospitalization at the ICU in the comparison (wards vs ICU) (right).

Figure legends

Figure 1: Forest plot showing the result from the multivariate generalized linear 599 model with a gamma distribution (log-link) to assess the association between 600 viremia and laboratory and immunological parameters Arithmetic mean ratios 601 (AMR) adjusted by major comorbidities (Age, Sex, Obesity, Hypertension, Type II 602 Diabetes, Cardiovascular disease, Asthma, Dyslipidemia) and disease severity category 603 604 (outpatients, ward and ICU) are showed in the plot. 605 Figure 2: Box plots showing the immunological mediators' levels across severity 606 groups. 607 Figure 3: prevalence of SARS-CoV-2-RNA viremia and SARS-CoV-2 IgG 608 antibodies in each severity group.














SARS-CoV-2 IgG (%)

